Download PDF
Semin Respir Crit Care Med 2012; 33(03): 284-291
DOI: 10.1055/s-0032-1315640
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Clinical Stability versus Clinical Failure in Patients with Community-Acquired Pneumonia

Stefano Aliberti
1   Dipartimento di Medicina Clinica e Prevenzione, University of Milan-Bicocca, San Gerardo Hospital, Monza, Italy.
,
Francesco Blasi
2   Respiratory Medicine Section, Dipartimento Toraco-Polmonare e Cardiocircolatorio, University of Milan, IRCCS Fondazione Ospedale Maggiore Policlinico Cà Granda, Milan, Italy.
› Author Affiliations
Further Information

Publication History

Publication Date:
20 June 2012 (online)

    Permissions and Reprints

Abstract

Once antibiotics have been started in patients with community-acquired pneumonia (CAP), the evaluation of clinical outcomes represents one of the essential steps in patient care. Among CAP patients who improve, recognition of clinical stability should be based on both subjective and objective parameters that are locally available in the everyday clinical practice. Different steps in the management of the pneumonia depend on this early outcome, including the switch from intravenous to oral antibiotics, patients' discharge from the hospital, and outcomes after hospitalization. When deterioration occurs in CAP patients, a “treatment failure” or a “clinical failure” should be identified. It is crucial to understand the etiology of failure so as to develop different measures at both international and local levels to prevent adverse outcomes. Finally, several efforts should be made to define incidence, timing, and risk factors for nonresolving pneumonia that, to date, remains one of the most indeterminate clinical outcomes in patients with CAP.

Keywords

community-acquired pneumonia - outcomes - failure - nonresolving pneumonia - stability
 

  • References

  • 1 Ramirez JA. Community-Acquired Pneumonia: A Plan for Implementing National Guidelines at the Local Hospital Level. Philadelphia, PA: Lippincott Williams & Wilkins; 2003
    Google Scholar
  • 2 Ramirez JA, Vargas S, Ritter GW , et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159 (20) 2449-2454
    CrossrefPubMedGoogle Scholar
  • 3 Halm EA, Fine MJ, Marrie TJ , et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279 (18) 1452-1457
    CrossrefPubMedGoogle Scholar
  • 4 Niederman MS, Mandell LA, Anzueto A , et al; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163 (7) 1730-1754
    CrossrefPubMedGoogle Scholar
  • 5 Mandell LA, Wunderink RG, Anzueto A , et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 02) S27-S72
    CrossrefPubMedGoogle Scholar
  • 6 Woodhead M, Blasi F, Ewig S , et al; European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2006; 27 (2) 439
    PubMedGoogle Scholar
  • 7 Lim WS, Baudouin SV, George RC , et al; Pneumonia Guidelines Committee of the BTS Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl. 03) iii1-iii55
    CrossrefPubMedGoogle Scholar
  • 8 Menéndez R, Martinez R, Reyes S , et al. Stability in community-acquired pneumonia: one step forward with markers?. Thorax 2009; 64 (11) 987-992
    CrossrefPubMedGoogle Scholar
  • 9 Menéndez R, Torres A, Rodríguez de Castro F , et al; Neumofail Group. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39 (12) 1783-1790
    CrossrefPubMedGoogle Scholar
  • 10 Viale P, Scudeller L, Petrosillo N , et al. Clinical stability in human immunodeficiency virus-infected patients with community-acquired pneumonia. Clin Infect Dis 2004; 38 (2) 271-279
    CrossrefPubMedGoogle Scholar
  • 11 Christensen D, Feldman C, Rossi P , et al; Community-Acquired Pneumonia Organization Investigators. HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the CAPO international cohort study. Clin Infect Dis 2005; 41 (4) 554-556
    CrossrefPubMedGoogle Scholar
  • 12 Arnold FW, Brock GN, Peyrani P , et al; CAPO authors. Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2010; 104 (11) 1736-1743
    CrossrefPubMedGoogle Scholar
  • 13 Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001; 161 (6) 848-850
    CrossrefPubMedGoogle Scholar
  • 14 Athanassa Z, Makris G, Dimopoulos G, Falagas ME. Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis. Drugs 2008; 68 (17) 2469-2481
    CrossrefPubMedGoogle Scholar
  • 15 Aliberti S, Peyrani P, Filardo G , et al. Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia. Chest 2011; 140 (2) 482-488
    CrossrefPubMedGoogle Scholar
  • 16 Aliberti S, Blasi F, Zanaboni AM , et al. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J 2010; 36 (1) 128-134
    CrossrefPubMedGoogle Scholar
  • 17 Genné D, Kaiser L, Kinge TN, Lew D. Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. Clin Microbiol Infect 2003; 9 (9) 949-954
    CrossrefPubMedGoogle Scholar
  • 18 Arancibia F, Ewig S, Martinez JA , et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162 (1) 154-160
    CrossrefPubMedGoogle Scholar
  • 19 Genné D, Sommer R, Kaiser L , et al. Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25 (3) 159-166
    CrossrefPubMedGoogle Scholar
  • 20 Hoogewerf M, Oosterheert JJ, Hak E, Hoepelman IM, Bonten MJ. Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia. Clin Microbiol Infect 2006; 12 (11) 1097-1104
    CrossrefPubMedGoogle Scholar
  • 21 Aliberti S, Amir A, Peyrani P , et al. Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest 2008; 134 (5) 955-962
    CrossrefPubMedGoogle Scholar
  • 22 Ott SR, Hauptmeier BM, Ernen C , et al. Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J 2012; 39 (3) 611-618
    CrossrefPubMedGoogle Scholar
  • 23 Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004; 164 (5) 502-508
    CrossrefPubMedGoogle Scholar
  • 24 Menéndez R, Cavalcanti M, Reyes S , et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008; 63 (5) 447-452
    CrossrefPubMedGoogle Scholar
  • 25 Hess G, Hill JW, Raut MK , et al. Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: results from a claims analysis. Adv Ther 2010; 27 (10) 743-755
    CrossrefPubMedGoogle Scholar
  • 26 Kaye KS, Harris AD, McDonald JR, Strausbaugh LJ, Perencevich E ; Infectious Diseases Society of America Emerging Infections Network. Measuring acceptable treatment failure rates for community-acquired pneumonia: potential for reducing duration of treatment and antimicrobial resistance. Infect Control Hosp Epidemiol 2008; 29 (2) 137-142
    CrossrefPubMedGoogle Scholar
  • 27 Ye X, Sikirica V, Schein JR , et al. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Clin Ther 2008; 30 (2) 358-371
    CrossrefPubMedGoogle Scholar
  • 28 Menéndez R, Torres A, Zalacaín R , et al; Neumofail Group. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 2004; 59 (11) 960-965
    CrossrefPubMedGoogle Scholar
  • 29 Mortensen EM, Coley CM, Singer DE , et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162 (9) 1059-1064
    CrossrefPubMedGoogle Scholar
  • 30 Ramirez J, Aliberti S, Mirsaeidi M , et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008; 47 (2) 182-187
    CrossrefPubMedGoogle Scholar
  • 31 Singanayagam A, Singanayagam A, Elder DH, Chalmers JD. Is community-acquired pneumonia an independent risk factor for cardiovascular disease?. Eur Respir J 2012; 39 (1) 187-196
    CrossrefPubMedGoogle Scholar
  • 32 Corrales-Medina VF, Suh KN, Rose G , et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011; 8 (6) e1001048
    CrossrefPubMedGoogle Scholar
  • 33 Garcia-Vidal C, Carratalà J. Early and late treatment failure in community-acquired pneumonia. Semin Respir Crit Care Med 2009; 30 (2) 154-160
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Menéndez R, Torres A, Zalacaín R , et al; NEUMOFAIL Group. Guidelines for the treatment of community-acquired pneumonia: predictors of adherence and outcome. Am J Respir Crit Care Med 2005; 172 (6) 757-762
    CrossrefPubMedGoogle Scholar
  • 35 Low DE, Mazzulli T, Marrie T. Progressive and nonresolving pneumonia. Curr Opin Pulm Med 2005; 11 (3) 247-252
    PubMedGoogle Scholar
  • 36 Kyprianou A, Hall CS, Shah R, Fein AM. The challenge of nonresolving pneumonia: knowing the norms of radiographic resolution is key. Postgrad Med 2003; 113 (1) 79-82 , 85–88, 91–92
    PubMedGoogle Scholar
  • 37 Salomoni G, Aliberti S, Travierso C , et al. Incidence, risk factors and outcomes of nonresolving pneumonia. Paper presented at: European Respiratory Society Annual Congress; September 18–22, 2010; Barcelona, Spain
    PubMedGoogle Scholar